Lupin launches Bromfenac Ophthalmic Solution

13 Feb 2024 Evaluate

Lupin has launched Bromfenac Ophthalmic Solution, 0.075%, after having received an approval from the United States Food and Drug Administration (U.S. FDA). Bromfenac Ophthalmic Solution, 0.075% is a generic equivalent of BromSite Ophthalmic Solution, 0.075%, of Sun Pharmaceutical Industries. It is indicated for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery. Bromfenac Ophthalmic Solution 0.075% (RLD BromSite) had estimated annual sales of $15 million in the U.S. (IQVIA MAT December 2023).

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. 

Lupin Share Price

2176.80 37.40 (1.75%)
22-Jan-2026 12:25 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1623.30
Dr. Reddys Lab 1221.90
Cipla 1376.65
Zydus Lifesciences 884.75
Lupin 2176.80
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×